DOACs vs Vitamin K Antagonists: a Comparison of Phase III Clinical Trials and a Prescriber Support Tool

Alina-Maria Pirlog¹, Cristian Daniel Pirlog², Marius Adrian Maghiar³

¹University of Oradea, Faculty of Medicine and Pharmacy, Department of General Medicine, Oradea, Romania; ²University of Oradea, Faculty of Medicine and Pharmacy, Department of Dentistry, Oradea, Romania; ³University of Oradea, Faculty of Medicine and Pharmacy, Department of General Surgery, Oradea, Romania

Abstract

AIM: The purpose of this article was to systematically review the literature assessing the efficacy and safety of phase III clinical trials for each direct oral anticoagulant versus vitamin K antagonists and to design a “go-to” table for the prescriber.

MATERIAL AND METHODS: A systematic review of specialist literature was conducted to identify RCTs which compared direct oral anticoagulants (DOACs) with standard warfarin treatment. Medline, Em-base, and the Cochrane databases were searched from January 2005- January 2019. The inclusion criteria were randomised controlled trials of oral anticoagulants in patients with non-valvular atrial fibrillation (NVAF). Four publications were phase III randomised control trials (RCTs) included in the final analysis.

RESULTS: Regarding the primary outcome in RELY the results were 1.69% per 100-year patients (p/y) for Warfarin compared to 1.11% p/y dabigatran etexilate 150mg BD (twice daily). In ROCKET AF the rates of the primary outcome were 1.60% p/y for warfarin compared to 1.27% p/y for apixaban 5 mg BD. In ENGAGE AF TIMI, the rates of the primary outcome were 1.50% p/y for warfarin compared to 1.18% p/y for edoxaban 60mg BD.

CONCLUSION: DOACs showed to be either noninferior or superior to warfarin with regards to the primary outcome with better safety patterns. Our “go-to” table provides a supportive tool for physicians in preventing medical errors when managing patients on oral anticoagulants.

Introduction

Atrial Fibrillation (AF) is one of the leading causes of cardiovascular morbidity and mortality worldwide [1]. The incidence and prevalence of AF have been increasing in recent years up to the point that one in four middle-aged adults in Europe and the US will develop this common cardiac arrhythmia [2], [3]. The above numbers reflect a growing number of patients requiring anticoagulants for stroke prevention.

The clinical management of patients with non-valvular AF (NVAF) has improved in recent years with the introduction of direct oral anticoagulant agents (DOACs) [4]. In the last decade, the four DOACs: dabigatran etexilate, rivaroxaban, apixaban and edoxaban have been used for the prevention of stroke and systemic embolism for people with NVAF with one or more risk factors: prior stroke or transient ischaemic attack; age 75 years or older; hypertension; diabetes mellitus; symptomatic heart failure [5].

Several characteristics distinguish DOACs from vitamin K antagonists (VKAs): rapid onset of action (1-3 h), do not require bridging with parenteral anticoagulants and there is no need for routine monitoring of anticoagulation. Additionally, DOACs have similar (7-15 h) half-lives and are partially eliminated by the kidney: 85% of dabigatran etexilate, 50% of edoxaban, 33% of rivaroxaban, and 27% of apixaban [5]. Patients who are taking Warfarin should be aware of the potential risks and benefits of switching to DOACs and their level of international
normalised ratio (INR) control taken into consideration when switching between anticoagulants [5], [6].

The availability of several drugs with similar efficacy and safety for stroke prevention in NVAF patients offers a selection for prescribers and users. Consequently, prescribers should have a good knowledge of these agents’ characteristics and the trials in which their use was established to counsel and care for the growing number of patients on oral anticoagulants.

The decision to take lifelong drugs such as oral anticoagulants should be made in collaboration between a patient and their doctor after an informed discussion about the risks and benefits of all the different drugs [7]. Medical professionals, particularly busy general practitioners/family doctors can find difficulties in keeping up to date with all the current guidelines and the new emerging drugs used in medical practice. If prescribers are better informed, then they can proficiently counsel their patients and collaborate with them when initiating an oral anticoagulant.

The purpose of this article was to systematically review the literature assessing the efficacy and safety of phase III clinical trials for each DOAC versus VKAs used in stroke prevention in patients with NVAF. Also, it aimed to design a “go-to” table for the prescriber to make an informed decision when comparing the oral anticoagulant drugs.

Material and Methods

A systematic review of specialist literature was conducted to identify phase III randomised control trials (RCTs) in patients receiving DOACs compared with standard warfarin treatment. Medline, Embase, and the Cochrane databases were searched from January 2005- January 2019 with no language restrictions using medical keywords to identify RCTs including "Dabigatran", "Rivaroxaban", "Apixaban", "Edoxaban", "Atrial Fibrillation", "Humans", "Randomized Controlled Trial". After combining the results and removing duplicates, the titles and abstracts were screened in 50 studies (Figure 1).

The full text of eight publications was retrieved and evaluated for eligibility, and four articles were phase III RCTs included in the final analysis. Studies had to meet the following inclusion criteria: randomised controlled trials of VKAs and DOACs in patients with NVAF. The research was excluded if patients were not followed up, if these were not randomised trials, and if papers were guidelines or any expert opinions.

Results

Four phases III clinical trials were evaluated, and in Table 1 and Table 2 we have compared the characteristics of phase III clinical trials for each DOAC that was on the market at the time of this study. Due to the heterogeneity of the key parameters, analysis of the statistical data was not attempted.

Table 1: Phase III clinical trials NOACs purpose and specific data characteristics

| Study Name | RELY 2009 | ROCKET AF 2011 | ARISTOTLE 2012 | ENGAGE AF TIMI 48 2013 |
|------------|-----------|----------------|----------------|------------------------|
| Purpose    | Dabigatran etexilate 150 mg BD or 110 mg BD to open-label dose adjusted Warfarin unblinded | Rivaroxaban 20 mg OD to dose-adjusted Warfarin | Apixaban 5 mg BD to dose-adjusted Warfarin | Edoxaban 30 mg OD and 60 mg OD to dose-adjusted Warfarin |
| Method-all were Prospectively randomised pivotal phase III clinical trial | Double-blind, double-dummy | Double-blind, double-dummy | Double-blind, double-dummy | Double-blind, double-dummy |
| Number of patients | 18113 | 14246 | 18201 | 21105 |
| Follow up (years) | 2.1 | 1.9 | 1.8 | 2.8 |
| CHADS2 | 56 | 3.5 | 2.1 | 2.8 |
| TTR (%) | 64% | 55% | 62% | 68% |
| Females (%) | 37% | 39% | 35% | 37% |
| Age mean (years) | 71 | 73 | 70 | 72 |
| Jadad score | 3 | 5 | 5 | 5 |

RELY (Randomised Evaluation of Long-Term Anticoagulation Therapy), ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in AF), ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF), ENGAGE AF-TIMI 48 (The Effective Anticoagulation with Factor Xa Next Generation in AF—Thrombolysis in Myocardial Infarction 46).

ROCKET-AF (rivaroxaban), ARISTOTLE (apixaban) and ENGAGE AF TIMI (edoxaban) were double-blind double-dummy trials. RELY (dabigatran etexilate) and ARISTOTLE trials had a similar number of patients of approximately 18100. The follow-up period in all trials ranged from 1.8-2.8 years. RELY and ARISTOTLE participants had an equal CHADS2...
Regarding the primary outcome in RELY the results were 1.69% per 100-year-patients (p/y) for warfarin compared to 1.53% p/y dabigatran etexilate 110 mg BD and 1.11% p/y dabigatran etexilate 150 mg BD. In ROCKET AF the rates of the primary outcome were 2.2% p/y for warfarin compared to 1.7% p/y for rivaroxaban 20 mg OD. In ARISTOTLE the rates of the primary outcome were 1.60% p/y for warfarin compared to 1.27% p/y for apixaban 5 mg BD. In ENGAGE AF TIMI the rates of the primary outcome were 1.50% p/y for warfarin compared to 1.18% p/y for edoxaban 60 mg BD and 1.61% p/y for edoxaban 30 mg BD. Taking into consideration all the important literature in oral anticoagulation for NVAF we designed a comprehensive but simple to follow "go-to" table (Table 3) [8], [9], [10], [11], [12], [13], [14], [15] to aid the prescribers worldwide.

### Table 2: Phase III clinical trials DOACs efficacy and bleeding rates

| Study Name and Phase | Primary Outcome | Bleeding/Number of Patients per Year |
|----------------------|-----------------|-------------------------------------|
| RELY 2009            | The rate of major bleeding: | 3.36% p/y warfarin 110 mg OB, 3.11% p/y dabigatran etexilale 150 mg BD, 3.09% p/y dabigatran etexilate 150 mg BD. Noninferiority: | 1.18% noninferiority. |
| ROCKET AF 2011       | The rate of major bleeding: | 3.75% p/y rivaroxaban 20 mg OD, 3.64% p/y dabigatran etexilate 150 mg BD. Noninferiority: | 2.1% noninferiority. |
| ARISTOTLE 2012       | The rate of major bleeding: | 3.90% p/y warfarin, 2.99% p/y rivaroxaban 20 mg OD, 2.88% p/y dabigatran etexilate 150 mg BD. Noninferiority: | 1.50% noninferiority. |
| ENGAGE AF TIMI 2013  | The rate of major bleeding: | 3.09% p/y rivaroxaban 20 mg OD, 2.79% p/y edoxaban 30 mg OD. Noninferiority: | 1.01% noninferiority. |

### Table 3: Oral Anticoagulants Specific Information A Prescriber Support Tool

| Drug | Bleeding Risk | Major Bleeding | Moderate Bleeding | Minor Bleeding | Intraprocedural Bleeding |
|------|---------------|---------------|------------------|---------------|--------------------------|
| Warfarin | No | Yes | Yes | Yes | Yes |
| Rivaroxaban | Yes | Yes | Yes | Yes | Yes |
| Apixaban | Yes | Yes | Yes | Yes | Yes |
| Edoxaban | Yes | Yes | Yes | Yes | Yes |

### Table 4: Selective Anticoagulants Use in Specific Populations

| Condition | Anticoagulant | Preferred Dose | Preferred Duration |
|----------|---------------|----------------|--------------------|
| Cancer | Warfarin | Yes | Yes |
| Pregnancy | Edoxaban | Yes | Yes |
| Renal Impairment | Dabigatran | Yes | Yes |

### Table 5: Reduced Dose of DOACs

| Drug | Reduced Dose | Reduced Duration |
|------|--------------|------------------|
| Warfarin | < 70 kg | Yes |
| Rivaroxaban | < 70 kg | Yes |
| Apixaban | < 70 kg | Yes |
| Edoxaban | < 70 kg | Yes |

### Table 6: Drug Interactions

| Drug | Potential Interactions |
|------|------------------------|
| Warfarin | Akamine, Chloramphenicol, Flucloxacillin, Ivermectin, Phenytoin, Warfarin, HIV, Ritonavir |
| Rivaroxaban | Ketoconazole, Fluconazole, Orlistat, Steroids |
| Apixaban | Ketoconazole, Fluconazole, Orlistat, Steroids |
| Edoxaban | Ketoconazole, Fluconazole, Orlistat, Steroids |

### Table 7: Anticoagulant Actions

| Drug | Anticoagulant Actions |
|------|-----------------------|
| Warfarin | Anticoagulant Actions |
| Rivaroxaban | Anticoagulant Actions |
| Apixaban | Anticoagulant Actions |
| Edoxaban | Anticoagulant Actions |
Discussion

**General characteristics of the four RCTs**

ROCKET AF, ARISTOTLE and ENGAGE AF TIMI were double-blind, double-dummy trials, whereas RELY was an open-label trial which suggested a possible bias for this trial. The RELY trial authors state the risk of bias was reduced by the implementation of several validated procedures, including blinded evaluation of outcome events [16]. RELY and ARISTOTLE trials had a similar number of patients of more than 18100, ROCKET AF had the smallest number of participants of 14246, whereas ENGAGE AF TIMI had the largest population of 21105 which showed that all trials were large trials of high importance. The follow-up period was similar in RELY, ROCKET AF and ARISTOTLE but considerably longer in ENGAGE AF TIMI at 2.8 years. RELY and ARISTOTLE participants had an equal CHADS2 score of 2.1. However, ENGAGE AF TIMI and ROCKET AF participants had a higher CHADS2 score of 2.8 and 3.5, respectively. This was a significant finding and should be taken into account when choosing a particular DOAC for a patient.

The mean percentage of TTR was lower in ROCKET-AF (55%) compared to TTR in ARISTOTLE (62%), RELY (64%) and ENGAGE AF TIMI (68%). This is also an important finding and should be taken into account particularly for patients who are switching from a VKA to a DOAC. In ROCKET AF the low TTR was interpreted as poor control of the patients anticoagulant status. Age and sex of the studied population were similar in all studies ranging from 70-73 years and female percentage between 35-39%. These numbers show similarities with the general epidemiological data in AF (2). Finally, all the RCTs obtained a good Jadad score.

**RE-LY**

For the primary outcomes, dabigatran etexilate 150 mg twice daily was superior to warfarin, and dabigatran etexilate 110 mg twice daily was noninferior to warfarin. Major bleeding was significantly decreased with the 110 mg twice daily dose of dabigatran etexilate. However, the group on the 150 mg twice daily dose of dabigatran etexilate showed increased major bleeding events compared to warfarin. The risk of hemorrhagic stroke was also significantly lower with both the 110 mg and 150 mg doses [16]. These findings show that dabigatran etexilate was noninferior or superior (150 mg BD) when compared to warfarin, but the bleeding risk should be considered in both anticoagulants.

Interestingly, the rate of myocardial infarction was higher with both doses of dabigatran etexilate compared with warfarin but not statistically significant. A reason for this was explained by Connolly et al., (RELY) that warfarin provides better protection against coronary ischaemic events compared to dabigatran [16] (Table 2).

Dabigatran etexilate capsules contain coating with tartaric acid to enhance the gastric absorption which requires a more acidic environment. This acidity may explain the increased incidence of dyspeptic symptoms with both dabigatran etexilate doses [16]. This should be taken into consideration when prescribing dabigatran etexilate in patients with known gastro-oesphagal pathology.

**ROCKET AF**

For the primary outcomes, the trial demonstrated noninferiority for rivaroxaban compared with warfarin in patients with NVAF who were at moderate to high risk for stroke. Major bleeding was similarly reported for rivaroxaban and warfarin groups. However, less fatal bleeding and less intracranial haemorrhage were found in the rivaroxaban group. In contrast, gastrointestinal (GI) bleeding was more frequently reported in the rivaroxaban group [17]. Consequently, extra caution should be taken when prescribing rivaroxaban in patients with previous GI bleeding (Table 2).

At the end of the trial, patients transitioning to open-label therapy had more strokes with rivaroxaban compared with warfarin [18]. Patel et al. explained that the difficulty in transitioning from blinded trial therapy to the open-label use of a VKA could have been the cause for this [17]. Presumably many patients who had previously been assigned to the warfarin group would have already had a therapeutic INR compared to the patients in the rivaroxaban group [17]. This should be taken into account when switching between anticoagulants.

**ARISTOTLE**

Granger et al described it was the only study of a DOAC that showed significantly lower rates of all-cause mortality reported at 3.52% in the apixaban group compared to 3.94% in the warfarin group [19]. Apixaban has shown to be significantly more effective than warfarin, with fewer overall strokes and systemic emboli by 21%, major bleeding events by 31% and decreased mortality by 11% [19]. Consequently, further studies showed positive findings for apixaban in comparing DOACs indirectly. A meta-analysis of the above trials indicated that there were no statistically significant differences between dabigatran etexilate, rivaroxaban or apixaban in the incidence of stroke, systemic embolism and all-cause mortality [6], [18]. Additionally, apixaban was associated with a significantly lower incidence of all bleeding outcomes compared with rivaroxaban and a lower incidence with clinically relevant non-major bleeding compared to dabigatran etexilate 150 mg twice daily [18].
**ENGAGE AF TIMI**

This was the largest DOAC trial, and it showed that both once-daily regimens of edoxaban were noninferior when compared with warfarin regarding the primary outcome. Of note, the follow-up period in this trial was long, and the TTR was higher compared to the previous three DOAC trials. This illustrated good management of patients on oral anticoagulants within the trial. Edoxaban regimens were associated with significantly lower rates of bleeding and mortality from cardiovascular causes compared to warfarin [18]. The rates of life-threatening bleeding, intracranial bleeding, and major bleeding plus clinically relevant non-major bleeding were significantly lower in the edoxaban group. However, the annualised rate of major gastrointestinal bleeding was higher with high dose edoxaban than with warfarin (1.51% vs 1.23%), but the gastrointestinal bleeding rate was lowest with low dose edoxaban (0.82%). Giugliano et al. stated that the rate of myocardial infarction was not altered with edoxaban, and there was no increase in the risk of stroke or bleeding when patients in the edoxaban groups made the transition to open-label anticoagulant therapy at the end of the study [20].

**DOACs and specific patient characteristics**

DOACs appeared to be equally or more effective and safer than Warfarin in preventing systemic embolism irrespective of the patients’ comorbidities [6], [16], [17], [18], [20]. Subsequently, “real world” studies showed that the risks of mortality, any bleeding, or major bleeding were significantly lower for apixaban and dabigatran etexilate compared with warfarin [18], [21]. We are in agreement with Shields et al. that direct comparison of the results from large, international, multicenter randomized control trials of DOACs versus warfarin for NVAF should be interpreted with caution due to differences in the mean CHADS2 score, TTR and rates of stroke and systemic embolism and hemorrhage in the warfarin group of the trials [15], [22].

In patients with NVAF with a significant risk of stroke, DOACs were reported as highly effective at preventing strokes compared to VKAs, and these provide a major improvement in the management of NVAF patients [23]. DOACs showed to have a more favourable safety profile and side effects, particularly for intracranial bleeding. Since the introduction of DOACs, there has been reported an increase in newly diagnosed patients with NVAF at risk of stroke who are receiving guideline-recommended therapy [4], [21].

Furthermore, due to the relatively recent introduction of these drugs, prescribers need to be aware of their characteristics, cautions and contraindications. Audits on prescribing oral anticoagulants reported frequent medical errors [23].

We agree with Heidbuchel et al., that the choice of the most appropriate DOAC for a patient should be based on the pharmacokinetics, pharmacodynamics and the integration of the clinical data concerning the patient’s characteristics [14]. Recommendations from EHRA (European Heart Rhythm Association) suggested that patients with a history or high risk of gastrointestinal bleeding may have a lower risk of bleeding complications with apixaban and low dose edoxaban compared with dabigatran etexilate, rivaroxaban or high dose edoxaban [14]. Moreover, there was reported some evidence that patients with a high risk for ischemic stroke may benefit from dabigatran etexilate 150 mg twice daily [24].

Regarding patient-centeredness, evidence was reported that patients adhere better to once daily medications compared with those medications taken twice daily. [25] Patient’s compliance was an important factor in the management of NVAF and data suggested in GARFIELD AF that patient refusal (11.2% for high-risk patients) has been the main patient factor affecting the rates of anticoagulation [4]. In patients without a contraindication to DOAC therapy, the selection among the agents was left primarily to physician and patient decision.

Wilke et al. reviewed the preferences of AF patients towards anticoagulation and showed that stroke risk reduction and limited bleeding risk were the most important attributes for an NVAF patient when deciding about oral anticoagulation [26]. NVAF patients were willing to accept higher bleeding risks if a certain threshold in reduced stroke risk could be reached [7], [26]. Steinberg et al. considered that involving the patient in the decision making when selecting a DOAC was vital for optimal management in NVAF [27]. Therefore this article encourages physicians to counsel patients about the risks and benefits of treatment and work out which is the best oral anticoagulant agent based on their characteristics (Table 3).

**Conclusion**

Based on the results in phase III randomised control trials discussed in this article, DOACs have shown similar efficacy but better safety patterns when compared with warfarin for NVAF management. To safely use anticoagulants, physicians should take into account patient-specific factors and shared decision making when prescribing an oral anticoagulant.

Our “go-to” table provides a supportive tool for physicians in preventing medical errors when managing patients on oral anticoagulants. Finally, research should be continued in clinical trials particularly for the specific populations.
Implications for Research

In this systematic review was summarised the important facts from the RCTs on oral anticoagulants. Also, a prescription tool was designed to aid family doctors/prescribers in choosing the right agent for the right patient.

Limitations

Although we comprehensively reviewed and summarised the literature, our search was not exhaustive, and new data are emerging rapidly.

Acknowledgements

This study has received no financial or material support and is based on previously conducted studies and not involving any new studies of human or animal subjects.

References

1. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Eur Heart J. 2012; 33:2719-47. https://doi.org/10.1093/eurheartj/ehs253 PMid:22922413
2. Collilla S, Crow A, Petkun W et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013; 112:1142-1147. https://doi.org/10.1016/j.amjcard.2013.05.063 PMid:23831166
3. Krijthe BP, Kunst A, Benjamin EJ et al. Projections on the future incidence and prevalence of atrial fibrillation in the U.S adult population. European Heart Rhythm Association practical guide on the use of anticoagulants in patients with non-valvular atrial fibrillation. Eur J Cardiovasc Prev Rehabil. 2015; 22:1467-1475. PMid:26324838
4. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Eur J Cardiovasc Prev Rehabil. 2015; 22:1467-1475. PMid:26324838
5. Shields AM, Lip GY. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation. Journal of internal medicine. 2015; 278(1):1-8. https://doi.org/10.1111/joim.12360 PMid:25758241
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S. Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2009; 361(12):1139-51. PMid:19717844
7. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Picpini JP, Becker RC. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine. 2011; 365(10):883-91. https://doi.org/10.1056/NEJMoa1107039 PMid:21830957
8. Lip GY, Mitchell SA, Liu X, et al. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol. 2016; 204:88-94. https://doi.org/10.1016/j.ijcard.2015.11.084 PMid:26655548
9. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011; 365(11):981-92. https://doi.org/10.1056/NEJMoa1107039 PMid:21870978
10. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2013; 369(22):2093-104. https://doi.org/10.1056/NEJMoa1310907 PMid:24251359
11. Camm AJ, Accetta G, Ambrosio G, et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart. 2017; 103(4):307-314. https://doi.org/10.1136/heartjnl-2016-309832 PMid:27641768 PMid:CPC:PMC5293840
12. Bisson A, Angoulvant D, Philippart R, et al. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation. Adv Ther. 2017; 34(6):1283-1290. https://doi.org/10.1007/s12325-017-0550-7 PMid:28493056 PMid:CPC:PMC5467882
13. Lip GY, Pan X, Kamble S, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin; a "real-world" observational study in the United States. Int J Clin Pract. 2016; 70(9):752-63. https://doi.org/10.1111/ijcp.12863 PMid:27550177
24. Schaefer JK, McBane RD, Wysokinski WE, et al. How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. Ann Haematol. 2016; 95:437-449. https://doi.org/10.1007/s00277-015-2566-x PMid:26658769 PMCid:PMC5129572

25. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-992. https://doi.org/10.1056/NEJMoa1107039 PMid:21870978

26. Wilke T, Bauer S, Mueller S, et al. Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review. Patient. 2017; 10(1):17-37. https://doi.org/10.1007/s40271-016-0185-9 PMid:27461276 PMCid:PMC5250672

27. Steinberg BA. How I use anticoagulation in atrial fibrillation. Blood. 2016; 128:2891-2898. https://doi.org/10.1182/blood-2016-07-693614 PMid:27780804